Ontology highlight
ABSTRACT:
SUBMITTER: Muller MC
PROVIDER: S-EPMC4916940 | biostudies-literature | 2009 Dec
REPOSITORIES: biostudies-literature
Müller Martin C MC Cortes Jorge E JE Kim Dong-Wook DW Druker Brian J BJ Erben Philipp P Pasquini Ricardo R Branford Susan S Hughes Timothy P TP Radich Jerald P JP Ploughman Lynn L Mukhopadhyay Jaydip J Hochhaus Andreas A
Blood 20090924 24
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with or without BCR-ABL mutations after prior imatinib. Among 1043 patients, 39% had a preexisting BCR-ABL mutation, including 48% of 805 patients with imatinib resistance or suboptimal response. Sixty-thre ...[more]